Cell Therapy Market Size Projected to Reach $38.24 billion by 2034 | 21.05%

According to Straits Research the global cell therapy market size was estimated at $6.88 billion in 2025 and is anticipated to grow from $8.29 billion in 2026 to $38.24 billion by 2034, registering a CAGR of 21.05% during the forecast period (2026–2034).

The therapeutic use of cells to address medical issues or illnesses is known as cell therapy. Cells or tissues are transplanted into a patient's body to repair or replace damaged cells or tissues. Cell therapy can potentially cure a wide range of ailments, including cancer, cardiovascular disease, neurological disorders, and autoimmune diseases. It consists of many different types of cells, including stem cells, immunological cells, and cells from other organs.

Market Dynamics

The  rising number of Clinical Studies for Cellular Therapies Drive the Global Market

Cellular treatments have a lot of therapeutic potential in various clinical settings. As a result, there has been a significant global investment in research and clinical translation. Rapid advances in stem cell research offer the potential to address unmet disease management requirements in the pharmaceutical, biotech, and medical industries. Clinical studies are being conducted on several undiscovered therapies. Moreover, the growth in the number of ongoing clinical trials can be ascribed to the continuing availability of grants from government and corporate funding sources to support initiatives at various phases of clinical trials. As a result, the aforementioned aspect will drive the global market.

Approval of Kymriah and Yescarta across Various Countries Creates Tremendous Opportunities

The encouraging outcomes of Kymriah and Yescarta in treating leukemia and lymphoma have resulted in rapid regulatory clearance for these medications in several nations. They have received FDA, EMA, Health Canada, and Japanese regulatory approval. Similarly, Kymriah will be approved by Chinese regulatory authorities in the next years. These approvals have resulted in a significant surge in studies for CAR T-cell treatments in a variety of malignancies.

In the coming years, therapeutic techniques based on adoptive cell transfer are anticipated to advance substantially. Kymriah was manufactured for 11 countries and 35 accredited treatment centers at the end of the first quarter of 2018. Such factors create opportunities for market growth over the forecast period.

Regional Analysis

North America is the most significant global cell therapy market shareholder and is estimated to exhibit a CAGR of 14.8% over the forecast period. The growing prevalence of chronic diseases, greater investment in research and development, and favorable government policies supporting cell therapy use are all driving factors in the North American cell therapy industry. Moreover, the large number of clinical trials conducted in North America promotes the region's market growth.

Furthermore, the rising desire for personalized treatment and public knowledge of the benefits of cell therapy is expected to provide new business opportunities in the field. The North American market is very competitive, with established and new competitors. The leading competitors in the industry are growing through joint ventures, acquisitions, and partnerships to obtain a competitive edge. Overall, the North American cell therapy market is expected to grow considerably in the coming years, owing to increased demand for innovative medications and a stronger emphasis on personalized medicine.

Market Segments

1. By Product
   1. Media, Sera, and Reagents
   2. Cell Engineering products
   3. Cell Culture Vessels
   4. Cell therapy Equipment
      1. Cell Processing Equipment
      2. Single-use equipment
      3. Other Equipment
   5. System and Software
   6. Other Products
2. By Cell Type
   1. T-Cells
   2. Stem Cells
   3. Other Cells
3. By Cell Process
   1. Cell Processing
   2. Cell Preservation, Distribution, and Handling
   3. Process Monitoring and Quality Control
4. By End User
   1. Biopharmaceutical and Biotechnology companies
   2. CRO’s and CMO’s
   3. Research Institutes & Cell Banks